U.S., July 31 -- ClinicalTrials.gov registry received information related to the study (NCT07093775) titled 'Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score' on July 15.
Brief Summary: To evaluated the prognostic significance of tumor grade in patients with node-negative, hormone receptor-positive, and human epidermal growth factor receptor 2-negative breast cancers treated according to RS-guided strategies.
Study Start Date: July, 2025
Study Type: OBSERVATIONAL
Condition:
Breast Cancer
Tumor Grade
Intervention:
OTHER: Tumor grade (I or II vs. III)
We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Gangnam Seve...